Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold

J Med Chem. 2009 Mar 26;52(6):1723-30. doi: 10.1021/jm801450c.


A series of IAP antagonists based on an azabicyclooctane scaffold was designed and synthesized. The most potent of these compounds, 14b, binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domain of c-IAP1 with K(i) values of 140, 38, and 33 nM, respectively. These compounds promote degradation of c-IAP1, activate caspases, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Finally, compound 14b inhibits tumor growth when dosed orally in a breast cancer xenograft model.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Administration, Oral
  • Azabicyclo Compounds / administration & dosage
  • Azabicyclo Compounds / chemistry*
  • Azabicyclo Compounds / pharmacokinetics
  • Biological Availability
  • Cell Line, Tumor
  • Humans
  • Inhibitor of Apoptosis Proteins / antagonists & inhibitors*
  • Models, Molecular
  • Octanes / chemistry*
  • Structure-Activity Relationship


  • Azabicyclo Compounds
  • Inhibitor of Apoptosis Proteins
  • Octanes

Associated data

  • PDB/3F7G
  • PDB/3F7H
  • PDB/3F7I